Experts criticise new German law for favouring drug companies

BMJ 2010; 341 doi: 10.1136/bmj.c5650 (Published 13 October 2010)
Cite this as: BMJ 2010;341:c5650

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Annette Tuffs
  1. 1Heidelberg

A new law on approving drugs for reimbursement by German insurance companies currently being debated in parliament could put the safety of patients at risk, experts have warned.

The law would substantially weaken the role of the German Institute for Quality and Efficiency in Health Care (IQWiG), the German equivalent of the UK National Institute for Health and Clinical Excellence, and lead to inefficient and dangerous drugs being approved, say experts.

An amendment to the law proposed by the governing coalition of the Christian Democrats and the liberal Free Democratic Party says that all new …

Access to the full text of this article requires a subscription or payment

Article access

Article access for 1 day

Purchase this article for £20 $30 €32*

The PDF version can be downloaded as your personal record

* Prices do not include VAT

THIS WEEK'S POLL